Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
SHANGHAI PECHEM
00338
5
SINOPEC CORP
00386
| (Q1)Mar 31, 2026 | (FY)Dec 31, 2025 | (Q9)Sep 30, 2025 | (Q6)Jun 30, 2025 | (Q1)Mar 31, 2025 | (FY)Dec 31, 2024 | (Q9)Sep 30, 2024 | (Q6)Jun 30, 2024 | (Q1)Mar 31, 2024 | (FY)Dec 31, 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Turnover | 128.53%665.91M | 29.88%1.76B | 18.87%1.19B | 31.90%797.52M | 50.51%291.39M | 2.95%1.36B | 0.30%1.01B | -24.27%604.63M | -52.55%193.61M | -52.36%1.32B |
| Operating income | 128.53%665.91M | 29.88%1.76B | 18.87%1.19B | 31.90%797.52M | 50.51%291.39M | 2.95%1.36B | 0.30%1.01B | -24.27%604.63M | -52.55%193.61M | -52.36%1.32B |
| Operating expenses | -126.22%-597.68M | -21.85%-1.59B | -11.42%-1.07B | -22.53%-719.47M | -40.58%-264.2M | -7.06%-1.3B | -3.48%-961.6M | 21.24%-587.19M | 51.09%-187.93M | 54.56%-1.22B |
| Gross profit | 150.90%68.23M | 220.85%175.71M | 183.52%123.36M | 347.72%78.05M | 379.13%27.2M | -46.19%54.76M | -40.28%43.51M | -67.05%17.43M | -76.18%5.68M | 12.54%101.78M |
| Selling expenses | -32.81%-3.93M | -8.37%-18.25M | 2.06%-10.95M | 8.50%-6.24M | -11.50%-2.96M | 9.73%-16.84M | 19.60%-11.18M | 29.65%-6.82M | 31.69%-2.66M | -6.13%-18.66M |
| Administrative expenses | -55.13%-12.46M | 66.49%-39.86M | 69.42%-29M | 71.93%-18.55M | 76.35%-8.03M | 47.86%-118.95M | 51.88%-94.81M | 51.37%-66.07M | 50.07%-33.95M | 17.02%-228.14M |
| Research and development expenses | -280.47%-8.81M | -59.30%-46.69M | -22.77%-26.41M | 8.21%-11.09M | 12.11%-2.31M | 17.39%-29.31M | 16.12%-21.51M | 22.07%-12.09M | 42.01%-2.63M | 14.82%-35.48M |
| Profit from asset sales | -97.53%75.4K | -23.05%4.21M | 2,452.14%4.16M | 2,422.76%4.11M | 1,771.90%3.05M | 181.57%5.47M | -49.93%163.08K | -49.93%163.08K | 95.08%163.08K | 172,605.68%1.94M |
| Revaluation surplus | ---- | ---23.52K | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- |
| -Changes in the fair value of other assets | ---- | ---23.52K | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- |
| Impairment and provision | -111.03%-217.22K | 97.02%-3.23M | 106.75%4.72M | 132.02%3.11M | 113.27%1.97M | 54.97%-108.47M | -1,470.68%-69.93M | -170.80%-9.7M | -11,455.13%-14.84M | -207.88%-240.91M |
| -Other impairment is provision | -111.03%-217.22K | 97.02%-3.23M | 106.75%4.72M | 132.02%3.11M | 113.27%1.97M | 54.97%-108.47M | -1,470.68%-69.93M | -170.80%-9.7M | -11,455.13%-14.84M | -207.88%-240.91M |
| Special items of operating profit | 156.84%690.32K | -90.35%26.12M | -99.28%2.09M | -99.56%1.27M | -99.90%268.77K | 97,365.08%270.68M | 217,738.64%289.12M | 217,379.47%288.65M | 810,360.01%282.23M | -59.51%277.72K |
| Operating profit | 125.32%39.72M | 90.21%91.93M | -50.37%63.95M | -76.90%47.84M | -92.42%17.63M | 111.11%48.33M | 171.62%128.86M | 272.35%207.1M | 508.03%232.58M | -29.60%-435.05M |
| Financing income | 77.68%539.16K | 31.33%1.39M | 30.14%1.06M | 40.59%799.54K | -57.94%303.44K | -76.81%1.06M | -80.75%810.69K | -80.46%568.7K | -35.36%721.36K | -45.70%4.55M |
| Financing cost | -34.20%-27.48M | 8.86%-93.84M | 7.73%-68.76M | 2.90%-45.32M | 2.61%-20.48M | 13.27%-102.96M | 4.32%-74.52M | 1.60%-46.67M | 20.65%-21.03M | -0.70%-118.71M |
| Special items of earning before tax | -97.01%217.5K | 987.73%7.5M | 79.69%7.33M | 128.02%7.25M | 197.49%7.28M | 176.68%689.51K | 180.16%4.08M | 144.31%3.18M | 1,139.80%2.45M | 80.15%-899.2K |
| Earning before tax | 4.11%5.61M | 110.72%5.1M | -91.76%5.29M | -92.88%12.04M | -97.51%5.39M | 91.35%-47.59M | 125.43%64.27M | 203.99%168.96M | 346.04%216.22M | -23.32%-550.08M |
| After-tax profit from continuing operations | 4.39%5.58M | 111.09%4.95M | -91.94%5.21M | -92.94%11.96M | -97.52%5.35M | 92.28%-44.64M | 125.37%64.61M | 203.30%169.35M | 342.14%216.13M | -28.87%-578.53M |
| Earning after tax | 4.39%5.58M | 111.09%4.95M | -91.94%5.21M | -92.94%11.96M | -97.52%5.35M | 92.28%-44.64M | 125.37%64.61M | 203.30%169.35M | 342.14%216.13M | -28.87%-578.53M |
| Minority profit | 101.40%1.03K | 78.17%-204.54K | 71.33%-224.64K | 74.17%-202.43K | 90.65%-73.3K | 91.97%-936.78K | 89.92%-783.42K | 86.23%-783.81K | 63.74%-783.86K | 51.29%-11.67M |
| Profit attributable to shareholders | 2.96%5.58M | 111.80%5.16M | -91.70%5.43M | -92.85%12.16M | -97.50%5.42M | 92.29%-43.7M | 126.49%65.4M | 207.52%170.13M | 349.05%216.91M | -33.39%-566.86M |
| Basic earnings per share | 2.94%0.007 | 120.00%0.01 | -91.71%0.0068 | -92.87%0.0152 | -97.50%0.0068 | 92.96%-0.05 | 126.49%0.082 | 207.51%0.2132 | 348.99%0.2719 | -33.96%-0.71 |
| Diluted earnings per share | 2.94%0.007 | 120.00%0.01 | -91.71%0.0068 | -92.87%0.0152 | -97.50%0.0068 | 92.96%-0.05 | 126.49%0.082 | 207.51%0.2132 | 348.99%0.2719 | -33.96%-0.71 |
| Currency Unit | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY |
| Accounting Standards | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) |
| Audit Opinions | -- | Unqualified Opinion | -- | -- | -- | Unqualified Opinion | -- | -- | -- | -- |
| Auditor | -- | PwC China (Special General Partnership) | -- | -- | -- | PwC China (Special General Partnership) | -- | -- | -- | ShinWing Certified Public Accountants (Special General Partnership) |
FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.
Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.